key: cord-0730013-2t4phhqp
authors: Chen, Elaine C.; Gilchuk, Pavlo; Zost, Seth J.; Suryadevara, Naveenchandra; Winkler, Emma S.; Cabel, Carly R.; Binshtein, Elad; Sutton, Rachel E.; Rodriguez, Jessica; Day, Samuel; Myers, Luke; Trivette, Andrew; Williams, Jazmean K.; Davidson, Edgar; Li, Shuaizhi; Doranz, Benjamin J.; Campos, Samuel K.; Carnahan, Robert H.; Thorne, Curtis A.; Diamond, Michael S.; Crowe, James E.
title: Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
date: 2021-05-03
journal: bioRxiv
DOI: 10.1101/2021.05.02.442326
sha: 4c7782d337dbf2745ec18587bd1c8c47becf4b9d
doc_id: 730013
cord_uid: 2t4phhqp

Unrelated individuals can produce genetically similar clones of antibodies, known as public clonotypes, which have been seen in responses to different infectious diseases as well as healthy individuals. Here we identify 37 public clonotypes in memory B cells from convalescent survivors of SARS-CoV-2 infection or in plasmablasts from an individual after vaccination with mRNA-encoded spike protein. We identified 29 public clonotypes, including clones recognizing the receptor-binding domain (RBD) in the spike protein S1 subunit (including a neutralizing, ACE2-blocking clone that protects in vivo), and others recognizing non-RBD epitopes that bound the heptad repeat 1 region of the S2 domain. Germline-revertant forms of some public clonotypes bound efficiently to spike protein, suggesting these common germline-encoded antibodies are preconfigured for avid recognition. Identification of large numbers of public clonotypes provides insight into the molecular basis of efficacy of SARS-CoV-2 vaccines and sheds light on the immune pressures driving the selection of common viral escape mutants.

the clones based on the inferred immunoglobulin heavy variable (IGHV) gene, immunoglobulin 150 heavy joining (IGHJ) gene, and the amino acid length of the heavy chain complementarity 151 determining region 3 (CDRH3). These sequences then were clustered according to 70% nucleotide 152 sequence identity in the DNA sequence encoding the CDRH3. Next, the sequences were binned 153 further based on the inferred immunoglobulin light variable gene (IGLV or IGKV) and 154 immunoglobulin light joining (IGLJ or IGKJ) genes. Clusters meeting these similarity criteria in 155 both heavy and light chains with sequences originating from two or more individuals were deemed 156 public clonotypes (Extended Data Fig.1) . Eleven public clonotypes were identified in the the inferred germline residue. We then tested if the germline revertants of the antibodies in each 287 group shared similar functional properties with their somatically-mutated counterparts. Each 288

germline-revertant antibody was tested for binding to SARS-CoV-2 S6Pecto, SARS-CoV-2 RBD, 289 or SARS-CoV-1 S2Pecto proteins. The Group 1 germline revertant did not bind to SARS-CoV-2 290

S6Pecto or SARS-CoV-1 S2Pecto. The Group 2 germline revertant maintained binding to both 291 SARS-CoV-2 and SARS-CoV-1 proteins but exhibited lower binding avidity (higher EC50 values) 292 than its matured counterparts COV2-2164 or CnC2t1p1_B10. The Group 3 germline revertant 293 maintained binding to SARS-CoV-2 S6Pecto and RBD proteins (Fig. 4a, d) . Each germline 294 revertant also bound to the surface of virus-infected cells (Fig. 4b,d) . While none of the germline 295 revertants exhibited neutralizing capacity (Fig. 4c, d) , the Group 3 germline revertant showed a 296 low level of ACE2 blocking (Fig. 4d,e) . 297

binding of some mAbs to the surface of virus-infected cells (Fig. 2e, h) suggested that these 299 antibodies also might act through Fc-mediated functions. Therefore, it was important to test some 300 public clonotypes in vivo. We tested the efficacy of these antibodies against SARS-CoV-2 in vivo. 301 We used K18-hACE2 transgenic mice, which develop severe lung infection and disease after 302 intranasal inoculation 48-50 . K18-hACE2 transgenic mice received either one antibody from Group 303 2 (COV2-2164), one antibody from Group 3 (COV2-2531), or an isotype-control 304 antibody (DENV 2D22) via intraperitoneal injection (200 µg, 10 mg/kg) one day prior to 305 intranasal inoculation with 10 3 PFU of SARS-CoV-2 (WA1/2020). Mice treated with COV2-2531 306 were protected completely from weight loss (Fig. 5a) and showed reduced viral infection in the 307 a reduction in viral load in the lung and brain (Fig. 5b, e) but not in the nasal wash and heart (Fig  310   5c, d) . Thus, antibodies that compete for binding with the SARS-CoV-1 mAb rCR3022 can be 311 elicited after SARS-CoV-2 infection, some of which can confer protection. 312

Public clonotypes shared between vaccine and convalescent responses to SARS-CoV-313 2 S protein. We hypothesized that SARS-CoV-2 mRNA vaccines might induce public clonotypes 314 that are shared with those seen in convalescent individuals after natural infection. We obtained 315 peripheral blood mononuclear cells from a volunteer 10 after first vaccine dose and 7 days after 316 second vaccine dose with the Pfizer-BioNTech vaccine. Circulating plasmablasts were enriched 317 directly from blood by negative selection using paramagnetic beads and purified further by flow 318 cytometric sorting (Fig. 6a, b) . Sorted plasmablasts were loaded on a Beacon microfluidics 319 instrument for single-cell secreted antibody binding screening and antibody gene sequencing or in 320 a Chromium single-cell microfluidics device (10X Genomics) followed by reverse transcription 321 with PCR and sequence analysis to obtain paired antibody sequences. These antibody discovery 322 workflows were described in detail previously 8 . Enzyme-linked immunospot (ELISpot) assay 323 analysis revealed large increase in the frequency of S-reactive cells in the enriched plasmablast 324 cell fraction on day 7 after the second vaccination compared to that on day 10 after the first vaccine 325 dose, confirming induction of target-specific responses in this individual. SARS-CoV-2 S6Pecto-326 specific secreted antibodies were of IgG and IgA classes and accounted for >10% of total 327 plasmablasts (Fig. 6c) . Further, single-cell antibody secretion analysis of a total of 4,797 purified 328 plasmablasts loaded on a Beacon microfluidics instrument (Berkeley Lights Inc.) revealed that a 329 large fraction of SARS-CoV-2-reactive clones (included S6Pecto-and/or RBD-reactive clones) 330 secreted RBD-specific IgG (Fig. 6d) . 331 We also analyzed antibody reactivity and neutralization in serum collected on the day 332 before vaccination (day 0), on day 10 after the first vaccine dose, on day 7 after the second vaccine 333 dose, and on day 28 after the second vaccine dose. The reactivity of serum antibodies to both 334 SARS-CoV-2 S6Pecto and SARS-CoV-2 RBD was measured by ELISA for binding (Fig. 6f) and 335 by VSV-SARS-CoV-2 neutralizing assay (Fig. 6g) . Binding and neutralizing activities steadily 336 increased over time, with maximal activity detected on day 28 after the second vaccine dose. 337

From single-cell antibody variable gene sequencing analysis, we obtained 725 paired heavy 338 and light chain sequences from plasmablasts following primary immunization and 8,298 paired 339 sequences from plasmablasts following the second dose of vaccine. The same procedure was 340 carried out on a sample collected 35 days after onset of symptoms from a convalescent individual 341 with confirmed SARS-CoV-2 infection. This individual's serum had been determined previously 342 to contain neutralizing antibodies 8 . Single-cell antibody secretion analysis revealed that a minor 343 fraction (0.5%) of total plasmablasts produced S-protein-reactive antibodies. We identified 1,883 344 paired heavy and light chain antibody sequences for this specimen. 345

Antibody sequences identified in these new studies and sequences we collected from 346 previous SARS-CoV-2 antibody discovery studies were clustered as described in Fig. 1 . We 347 identified a total of 37 public clonotypes, 26 of which represented clonotypes shared between 348 antibodies isolated from the vaccinee and individuals with exposure history to natural SARS-CoV-349 2 infection (Fig. 6h) . The antigen-binding specificity of each group was inferred through review 350 of data in each respective publication in which the antibodies were reported. We determined that 351 14 of the 26 newly-identified shared clonotypes encoded antibodies specific to the SARS-CoV-2 352 S protein. Within that panel of mAbs, 8 of 26 clonotypes reacted with SARS-CoV-2 RBD protein, 353 and 6 of the 26 public clonotypes cross-reacted with both SARS-CoV-1 and SARS-CoV-2 (Fig. 7) . Most antibodies shared in public clonotypes were IgG, with a subset of IgAs noted. This finding 355

shows that the Pfizer-BioNTech vaccine induces many antibodies that are genetically similar to 356 ones elicited through natural SARS-CoV-2 infection, including multiple public clonotypes in 357 convalescent donors encoded by commonly used VH genes such as IGHV3-53, IGHV3-66, IGHV1-358 58, IGHV3-30, and IGHV3-30-3. Additionally, of the 37 total public clonotypes, 16 bound to RBD, 359 and of these, 11 of 16 were neutralizing. All neutralizing public clonotypes recognized RBD. 360

However, of the 37 public clonotypes identified, 21 are directed to antigenic sites other than the 361 RBD, including ones described here directed to the S2 domain. It is likely that although a 362 substantial portion of neutralizing public clonotypes is directed to the RBD, non-RBD-targeted 363 and non-neutralizing public clonotypes may make up an even larger portion of an individual's 364 response to either vaccination or infection. Overall, these results suggest that many of the public 365 clonotypes observed in previously infected individuals likely are found in vaccinated individuals. 366

The high number of identified public B cell clonotypes in the response to SARS-CoV-2 369 infection or vaccination is striking, and the frequency of public clonotypes identified here is much 370 higher than in randomly sampled B cells in a convalescent donor 8 . Many public clonotypes are 371 shared between both infected and vaccinated individuals. Public clonotypes appear to be induced 372 by each of the currently known antigenic sites on the S protein and are found in both the 373 neutralizing and non-neutralizing repertoires. Some clonotypes in the shared SARS-CoV-2 374 response appear preconfigured in the germline state to recognize particular S epitopes, and this 375 recognition likely is driven by particular structural features on S. The scale of available relatively 376 large repertoire data for SARS-CoV-2 enabled us to identify many public clonotypes. The SARS-CoV-2 pandemic has resulted in comprehensive studies of antibody responses to SARS-CoV-2 S 378 protein, with many groups identifying large panels of mAbs, including potently neutralizing ones 8-379 12,38,40,41 . These discovery efforts have led to the identification of large paired heavy and light chain 380 antibody variable gene sequence data sets for B cells specific to SARS-CoV-2, and the data has 381 been made public at a scale unlike that for any other virus. In this study we compared the sequences 382 of more than 14,000 paired B cell sequences encoding antibodies to S protein of SARS-CoV-2. 383

Likely, this influx in the availability of paired antibody gene sequences from a multitude of donors 384 contributed to our ability to identify an unexpectedly high number of paired-sequence public 385 clonotypes. It will be interesting in future to use paired sequencing to determine if the scale of 386 shared repertoire we observed here for SARS-CoV-2 is a more pronounced feature of the response 387 to this particular virus than that of other viruses that have been studied for shared clones, such as 388 HIV-1, influenza, and hepatitis C. Previous studies have identified public clonotypes in the 389 response to these other viral pathogens, for example a recent study of response to HIV 26-29 in which 390 27 public clonotypes were described with unpaired sequencing using only the heavy chain CDR3 391 sequence and VH/JH gene usage 26 . 392

Several neutralizing public clonotypes have be identified previously, most commonly 393 clonotypes encoded by the closely related heavy chain genes IGHV3-53, IGHV3-66 32,37 , IGHV1-394 2 51 , and IGHV3-30 9 . Structural features of these public clonotypes likely drive the frequent 395 selection of such clones, such as the canonical configuration of aromatic residues in the public 396 clonotype IGHV1-58 + IGHJ3 and IGKV3-20 + IGKJ1 that engages the SARS-CoV-2 RBD F486 397 residue 33 . Members of this public clonotype, such as COV2-2196, engage the RBD using 398 predominantly germline-encoded residues in both the heavy and light chain 9, 33, 34, 39, 52 .

to humoral responses that mediate protection if they appear not only in memory B cells but also as 401 antibodies from plasma cells secreted into the serum 53 . The high prevalence of public clonotypes 402 elicited to the SARS-CoV-2 S trimer may contribute to the high efficacy of S-encoding mRNA 403 vaccines in large populations. 404

The recognition pattern of public clonotypes may predict the emergence of particular 405 antibody escape virus variants. If diverse individuals independently make the same antibody in 406 response to an antigen, there could be a constant and collective selective pressure on that epitope, 407 resulting in a high potential for escape variants at that site. For example, while IGHV3-53-and 408 IGHV3-66-encoded public clonotypes have been described in numerous individuals, neutralization 409 of these antibodies is impacted adversely by the K417N or K417T substitutions present in the 410 B.1.351 or P.1 SARS-CoV-2 variants of concern, respectively 54 . A similar case was described for 411 IGHV1-2-encoded antibodies that target the RBD and IGHV1-24-encoded antibodies that target 412 the NTD. These antibodies are found in the serum of convalescent individuals 53 , but neutralization 413 of these antibodies is negatively affected for 501Y.V2 variant viruses 55 . A possible explanation 414 for the selective pressure that led to the emergence and propagation of these variants is the humoral 415 immunity mediated by these public clonotypes. 416

The new Group 3 public clonotype neutralizing and protective antibodies described here 417 bind to the cryptic face of the RBD and compete with the SARS-CoV-2 non-neutralizing mAb 418 CR3022. Neutralizing antibodies that bind to the more conserved base of the RBD are of interest, 419 as these sites are largely unaffected by common mutations in the variants of concern such as 420 E484K, K417N, and N501Y 54 . Importantly, recent work has identified a B.1.1.7 variant with a 421 deletion of RBD residues 375-377. This deletion disrupts the epitope of CR3022, yet appears to 422 be functionally tolerated 56 . As Group 3 antibodies share a similar epitope, with critical residues of COV2-2531 and C126 being K378 and A372, but with additional critical residues of Y369, N370, 424 F374, and P384 identified for C126, this deletion might abrogate binding of antibodies from this 425 public clonotype. Further study of public clonotypes may give insight into the most likely sites of 426 future major antigenic changes in circulating field strains. 427

While public clonotypes have been described that recognize the RBD 33,9,32,37,51 and 428 NTD 53,57,58 of the S trimer, to our knowledge, those specific to the S2 domain have not been 429 described. In this study, we identified two public clonotypes, designated here as Groups 1 and 2, 430 which target the S2 domain of the S trimer. These mAbs do not neutralize, but they react with S 431 proteins of both SARS-CoV-2 and SARS-CoV-1. It is likely that these S2 epitopes are the target 432 (1) neutralizing public clonotypes that bind to relatively invariant sites on S, (2) 447 neutralizing public clonotypes that bind to sites that tolerate high sequence variability, (3) non-448 neutralizing public clonotypes that target relatively invariant sites, and (4) non-neutralizing public 449 antibodies that target variable sites. The first class of antibodies is likely the most protective class 450 in a population, as these mAbs neutralize and recognize residues unlikely to be sustained with 451 mutations due to loss of viral fitness. An example of this class would be IGHV1-58-encoded 452 antibodies as described previously 33 . Many public clones currently identified for SARS-CoV-2 are 453 categorized in the second class. While these clones initially offer protection, this property could 454 be lost as widespread selective pressure on the virus is exerted on a region with genetic and 455 structural plasticity. Examples of this group were discussed here, such as IGHV3-53-and IGHV3-456 66-encoded antibodies that target the RBD 54 . Here, we described three new public clonotypes 457 following natural infection (Groups 1, 2, and 3) and a total of 29 new clonotypes after mRNA 458 vaccination. Public clonotype Groups 1 and 2 fall into the third class of antibodies described here 459 (non-neutralizing antibodies that target invariant sites), and public clonotype Group 3 antibodies 460 falls into the second class (neutralizing public clonotypes that bind to variable sites). Future public 461 clonotypes to SARS-CoV-2 could be binned with this four-quadrant scheme to better understand 462 how public clonotypes contribute to humoral immunity against COVID-19. 463

Understanding the antibody response that is shared between convalescent and vaccinated 464 individuals also will be of continued interest as the percentage of vaccinated individuals increases 465 in the facing of emergence of new viral variants of concern. The understanding of viral epitopes 466 that induce protective antibodies in multiple individuals has implications for predicting the most with acquired mutations in epitopes for neutralizing antibodies, including antibody regimens 469 currently authorized for EUA, is a cause for concern 61-64 . Our analyses of public clonotypes after 470 natural infection and vaccination and their shared epitope targets may predict sites of future major 471 antigenic changes in the S trimer. were inoculated with SARS-CoV-2. Antibody concentrations started at 10 µg/mL and were 564 titrated three-fold. 565 d. Antibody binding to full-length S (grey) or S protein C-terminus S2 region (red) expressed 566 on the surface of HEK-293T cells that were fixed and permeabilized. Antibodies were 567 screened at 1 µg/mL. Antibody reactivity was measured by flow cytometry and cellular 568 florescence values were determined. COV2-2490, an NTD-directed antibody, was used as 569 a control. 570 e. Binding to VSV-SARS-CoV-2-infected Vero cells (SARS-CoV-2 WT) was measured 571 using flow cytometry and median florescence intensity values were determined for dose-572 response binding curves. Antibody was diluted 3-fold staring from 10 µg/mL 573 f. Binding to S protein C-terminus S2 region expressed on HEK-293T cells (SARS-CoV-2 574 WT S2) was measured using flow cytometry and mean fluorescence intensity values were 575 determined for dose-response binding curves. Antibody was diluted 3-fold starting from 576 10 µg/mL. 577 g. Inhibition of ACE2 binding curves for COV2-2531 or C126. Antibody concentrations 578 started at 10 µg/mL and were titrated 3-fold to identify ACE2 blocking curves. COV2-579 2531 is shown in light orange, and C126 is shown in dark orange. 580 h. Binding EC50 and neutralization IC50 values for each of the assay curves in Fig 3a, b, c, d were first binned all sequences by the same heavy chain V and J genes. Following sequences then 824 were clustered according to 70% sequence similarity on their CDRH3 nucleotide sequence. Lastly, 825 sequences then were binned together again if they used the same light chain V and J genes. Clusters 826 of sequences containing sequences from two or more donors were determined to be public 827

Heat map generation. All sequences that were identified to be public clonotypes were 829 analyzed with PyIR 66 to identify the V and J genes. The number of sequences with corresponding 830 V and J genes on the heavy and light chains were counted. These frequency counts then were 831 plotted onto the heatmap using Python Seaborn Library. 832 Plates were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS containing 853 0.05% Tween-20 for 1 h. All antibodies were diluted to a concentration of either 0.4 µg/mL for 854 the matured antibodies or 5 µg/mL for the germline-revertant antibodies. Antibodies were diluted 855 in two-fold dilutions until binding was no longer detected. Bound antibodies were detected using 856 goat anti-human IgG conjugated with horseradish peroxidase and TMB substrate. The reaction 857 was quenched with 1N hydrochloric acid once color was developed. The absorbance was measured 858 at 450 nm using a spectrophotometer (Biotek). Competition-binding ELISA. Wells of 384-well microtiter plates were coated with 894 purified recombinant SARS-CoV-2 S6Pecto protein at 4°C overnight. Plates were blocked with 2% 895 bovine serum albumin (BSA) in DPBS containing 0.05% Tween-20 for 1 h. Each antibody was 896 diluted to a concentration of 10 µg/mL. Next, biotinylated antibodies were diluted to 2.5 µg/mL 897 and added to the primary antibody solution without washing the plate to a final concentration of 898 0.5µg/mL. Biotinylated antibody binding was detected with horseradish peroxidase-conjugated 899 avidin (Sigma) and developed with TMB. The reaction was quenched with 1N hydrochloric acid 900 once color was developed. Absorbance was measured at 450 nm using a spectrophotometer. 901 ACE2 blocking assay. Wells of 384-well microtiter plates were coated with purified 902 recombinant SARS-CoV-2 S6Pecto protein at 4°C overnight. Plates were blocked with 2% nonfat 903 dry milk in DPBS containing 0.05% Tween-20 for 1 h. Each antibody was diluted to a 904 concentration of 10 µg/mL. Next, recombinant human ACE2 protein with a C-terminal FLAG tag 905 was diluted to 2 µg/mL and added to the antibody solution without washing the plate to a final 906 concentration of ACE2 of 0.4µg/mL. ACE2 binding was detected using HRP-conjugated anti-907 FLAG antibodies and developed with TMB substrate. The reaction was quenched with 1 N 908 hydrochloric acid once color was developed. Absorbance was measured at 450 nm using a 909 spectrophotometer. to 15 μg/mL was applied to a glow-discharged grid with continuous carbon film on 400 square 962 mesh copper electron microscopy grids (Electron Microscopy Sciences). The grids were stained 963 with 0.75% uranyl formate 69 . Images were recorded on a Gatan US4000 4k × 4k CCD camera 964 using an FEI TF20 (TFS) transmission electron microscope operated at 200 keV and control with 965 Serial EM. All images were taken at 50,000× magnification with a pixel size of 2.18 Å per pixel 966 in low-dose mode at a defocus of 1.5 to 1.8 μm. The total dose for the micrographs was 967 around 30 e− per Å 2 . Image processing was performed using the cryoSPARC software package.

with a box size of 256 pixels and binned to 128 pixels (pixel size of 4.36 Å/pix) and 2D class 970 averages were performed. 971 Epitope mapping of antibodies by alanine scanning. Epitope mapping was performed 972 essentially as described previously 70 using SARS-CoV-2 (Wuhan-Hu-1 strain) S protein RBD and 973 S2 shotgun mutagenesis mutation libraries, made using a full-length expression construct for S 974 protein. 184 residues of the RBD (between S residues 335 and 526), and 513 S2 residues (between 975 residues 689 -1247) were mutated individually to alanine, and alanine residues to serine. concentrations were determined using an independent immunofluorescence titration curve against 984 cells expressing wild-type S protein to ensure that signals were within the linear range of detection. 985

Antibodies were detected using 3.75 μg/mL of Alexa-Fluor-488-labeled secondary antibodies 986 (Jackson ImmunoResearch Laboratories) in 10% normal goat serum with 0.1% saponin. Cells 987 were washed three times with PBS++/0.1% saponin followed by two washes in PBS, and mean 988 cellular fluorescence was detected using a high-throughput Intellicyte iQue flow cytometer 989 (Sartorius). Antibody reactivity against each mutant S protein clone was calculated relative to 990 wild-type S protein reactivity by subtracting the signal from mock-transfected controls and identified as critical to the mAb epitope if they did not support reactivity of the test MAb but supported reactivity of other SARS-CoV-2 antibodies. This counter-screen strategy facilitates the 994 exclusion of S protein mutants that are locally misfolded or have an expression defect. ...........................................................................E.........HK.....PS............  ...............................................................................................PA............   NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNVVFGGGTKLTVL  .......................GN..................A........S........................................F..G.............  .......................G...................A.....N........................................... 

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 1093 spike

Characterization of neutralizing antibodies from a SARS-CoV-2 infected 1095 individual. bioRxiv

Broad neutralization of SARS-related viruses by human monoclonal 1097 antibodies

Regeneron's casirivimab and imdevimab antibody 1099 cocktail for COVID-19 is first combination to receive FDA emergency use authorization

A phase 3 randomized, double-blind, placebo-controlled trial to 1103 evaluate the efficacy and safety of LY3819253 alone and in combination with LY3832479 1104 in preventing SARS-CoV-2 infection and COVID-19 in skilled nursing and assisted living 1105 facility residents and staff; a NIAID and Lilly Collaborative Study

Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older

Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in 1118 the first interim analysis of the phase 2 COVE study

Structural basis for a convergent immune response against Ebola 1122 virus

Polyclonal and convergent antibody response to Ebola virus vaccine 1124 rVSV-ZEBOV

Longitudinal analysis of the human B cell response to Ebola virus 1126 infection

Canonical features of human antibodies 1131

Structural and functional bases for broad-spectrum neutralization of avian and 1138 human influenza A viruses

H5N1 vaccine-elicited memory B cells are genetically constrained 1141 by the IGHV locus in the recognition of a neutralizing epitope in the hemagglutinin stem

Multi-donor longitudinal antibody repertoire sequencing reveals the 1144 existence of public antibody clonotypes in HIV-1 infection

Focused evolution of HIV-1 neutralizing antibodies revealed by structures 1147 and deep sequencing

Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 1149

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity 1151 by gp41-microbiota cross-reactive antibodies

Broadly neutralizing antibodies with few somatic mutations and hepatitis 1154 C virus clearance

Genetic and structural basis for recognition of SARS-CoV-2 spike protein 1161 by a two-antibody cocktail. bioRxiv

B cell clonal expansion and convergent antibody responses to 1163

SARS-CoV-2. Res Sq

High frequency of shared clonotypes in human B cell receptor repertoires

Commonality despite exceptional 1167 diversity in the baseline human antibody repertoire

Sequence signatures of two

CoV-2 receptor binding domain. bioRxiv

Potent neutralizing antibodies from COVID-19 patients define 1172 multiple targets of vulnerability

Potently neutralizing and protective human antibodies against SARS-CoV-1184 2

Integrated pipeline for the accelerated discovery of antiviral antibody 1186 therapeutics

Epitope-resolved profiling of the SARS-CoV-2 antibody response 1188 identifies cross-reactivity with endemic human coronaviruses

Studies in humanized mice and convalescent humans yield a SARS-CoV-1191 2 antibody cocktail

DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes 1193 dengue virus type 2 by locking E protein dimers

A highly conserved cryptic epitope in the receptor binding domains of 1196

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe 1199 lung inflammation and impaired function

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 1202 mice

Human angiotensin-converting enzyme 2 transgenic mice infected with 51

Modular basis for potent SARS-CoV-2 1209 neutralization by a prevalent VH1-2-derived antibody class

Ultrapotent human antibodies protect against SARS-CoV-2 1211 challenge via multiple mechanisms

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 1214 non-RBD spike epitopes in COVID-19 convalescent plasma. bioRxiv

Structural and functional ramifications of antigenic drift in recent SARS-1217

CoV-2 variants. bioRxiv

SARS-CoV-2 501Y.V2 escapes neutralization by South African 1219 COVID-19 donor plasma. bioRxiv

Deletion disrupts a conserved antibody epitope in a SARS-CoV-2 variant of concern

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-1224

Terminal Domain Target a Single Supersite

Reverse 1230 vaccinology 2.0: Human immunology instructs vaccine antigen design

Seasonal human coronavirus antibodies are boosted upon SARS-1233

CoV-2 infection but not associated with protection

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited 1236 antibodies

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

Emergence of a SARS-CoV-2 variant of concern with mutations in spike 1240 glycoprotein

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating 1242 variants

Neutralizing antibody and soluble ACE2 inhibition of a replication-1244 competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 1245 28

PyIR: a scalable wrapper for processing billions of immunoglobulin and T 1247 cell receptor sequences using IgBLAST

Growth, detection, 1252 quantification, and inactivation of SARS-CoV-2

Negative staining and image classification -1255

Powerful tools in modern electron microscopy

A high-throughput shotgun mutagenesis approach to mapping 1258

ELISA binding assay for serum analysis. To assess serum reactivity, 384-well microtiter 1002 plates were coated with purified recombinant SARS-CoV-2 S6Pecto at 4˚c overnight. Plates were 1003 blocked with blocking buffer (2% non-fat dry milk and 2% normal goat serum in DPBS containing 1004 0.05% Tween-20) for 1 h. Serum was diluted 1:75 in blocking buffer, and then diluted three-fold 1005 serially 15 times, and added to wells. Binding was detected with goat anti-human IgG conjugated 1006 with horseradish peroxidase and TMB substrate. The reaction was quenched with 1N hydrochloric 1007 acid once color was developed. The absorbance was measured at 450 nm using a 1008 1016 (StemCell Technologies)